

Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GC0F93058FA2EN.html>

Date: July 2024

Pages: 125

Price: US\$ 3,200.00 (Single User License)

ID: GC0F93058FA2EN

Abstracts

Report Overview:

The Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size was estimated at USD 4221.19 million in 2023 and is projected to reach USD 9612.04 million by 2029, exhibiting a CAGR of 14.70% during the forecast period.

This report provides a deep insight into the global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are

planning to foray into the Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) market in any manner.

Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Qiagen NV

GE Healthcare

Agilent Technologies

F Hoffman La Roche

Foundation Medicine

Thermo Fisher Scientific Inc.

Leica Biosystems Nussloch GmbH

Pfizer

Market Segmentation (by Type)

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Market Segmentation (by Application)

Oncology

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market

Overview of the regional outlook of the Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business

expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx)

1.2 Key Market Segments

1.2.1 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Segment by Type

1.2.2 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET COMPETITIVE LANDSCAPE

3.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Manufacturers (2019-2024)

3.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Revenue Market Share by Manufacturers (2019-2024)

3.3 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Pharmacogenomics Technology and Theranostics and Companion

Diagnostics (CDx) Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Sites, Area Served, Product Type

3.6 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Competitive Situation and Trends

3.6.1 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Concentration Rate

3.6.2 Global 5 and 10 Largest Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) INDUSTRY CHAIN ANALYSIS

4.1 Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Type (2019-2024)

6.3 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Market Share by Type (2019-2024)

6.4 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Price by Type (2019-2024)

7 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Sales by Application (2019-2024)

7.3 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD) by Application (2019-2024)

7.4 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Growth Rate by Application (2019-2024)

8 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET SEGMENTATION BY REGION

8.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region

8.1.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region

8.1.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Region

8.2 North America

8.2.1 North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Qiagen NV

9.1.1 Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

9.1.2 Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

9.1.3 Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance

9.1.4 Qiagen NV Business Overview

9.1.5 Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis

9.1.6 Qiagen NV Recent Developments

9.2 GE Healthcare

- 9.2.1 GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information
- 9.2.2 GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview
- 9.2.3 GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance
- 9.2.4 GE Healthcare Business Overview
- 9.2.5 GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis
- 9.2.6 GE Healthcare Recent Developments
- 9.3 Agilent Technologies
 - 9.3.1 Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information
 - 9.3.2 Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview
 - 9.3.3 Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance
 - 9.3.4 Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis
 - 9.3.5 Agilent Technologies Business Overview
 - 9.3.6 Agilent Technologies Recent Developments
- 9.4 F Hoffman La Roche
 - 9.4.1 F Hoffman La Roche Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information
 - 9.4.2 F Hoffman La Roche Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview
 - 9.4.3 F Hoffman La Roche Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance
 - 9.4.4 F Hoffman La Roche Business Overview
 - 9.4.5 F Hoffman La Roche Recent Developments
- 9.5 Foundation Medicine
 - 9.5.1 Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information
 - 9.5.2 Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview
 - 9.5.3 Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance
 - 9.5.4 Foundation Medicine Business Overview
 - 9.5.5 Foundation Medicine Recent Developments

9.6 Thermo Fisher Scientific Inc.

9.6.1 Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

9.6.2 Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

9.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance

9.6.4 Thermo Fisher Scientific Inc. Business Overview

9.6.5 Thermo Fisher Scientific Inc. Recent Developments

9.7 Leica Biosystems Nussloch GmbH

9.7.1 Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

9.7.2 Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

9.7.3 Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance

9.7.4 Leica Biosystems Nussloch GmbH Business Overview

9.7.5 Leica Biosystems Nussloch GmbH Recent Developments

9.8 Pfizer

9.8.1 Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

9.8.2 Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

9.8.3 Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Market Performance

9.8.4 Pfizer Business Overview

9.8.5 Pfizer Recent Developments

10 PHARMACOGENOMICS TECHNOLOGY AND THERANOSTICS AND COMPANION DIAGNOSTICS (CDX) MARKET FORECAST BY REGION

10.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast

10.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country

10.2.3 Asia Pacific Pharmacogenomics Technology and Theranostics and Companion

Diagnostics (CDx) Market Size Forecast by Region

10.2.4 South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Type (2025-2030)

11.1.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Type (2025-2030)

11.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Forecast by Application (2025-2030)

11.2.1 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) Forecast by Application

11.2.2 Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Comparison by Region (M USD)

Table 5. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) as of 2022)

Table 10. Global Market Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Sites and Area Served

Table 12. Manufacturers Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Type

Table 13. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx)

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Challenges

Table 22. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Type (K Units)

Table 23. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size by Type (M USD)

Table 24. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) by Type (2019-2024)

Table 25. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Type (2019-2024)

Table 26. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD) by Type (2019-2024)

Table 27. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Share by Type (2019-2024)

Table 28. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Price (USD/Unit) by Type (2019-2024)

Table 29. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) by Application

Table 30. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size by Application

Table 31. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Application (2019-2024) & (K Units)

Table 32. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Application (2019-2024)

Table 33. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Application (2019-2024) & (M USD)

Table 34. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Application (2019-2024)

Table 35. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Growth Rate by Application (2019-2024)

Table 36. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region (2019-2024) & (K Units)

Table 37. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Region (2019-2024)

Table 38. North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Country (2019-2024) & (K Units)

Table 39. Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region (2019-2024) & (K Units)

Table 41. South America Pharmacogenomics Technology and Theranostics and

Companion Diagnostics (CDx) Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales by Region (2019-2024) & (K Units)

Table 43. Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 44. Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 45. Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. Qiagen NV Business Overview

Table 47. Qiagen NV Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis

Table 48. Qiagen NV Recent Developments

Table 49. GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 50. GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 51. GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. GE Healthcare Business Overview

Table 53. GE Healthcare Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis

Table 54. GE Healthcare Recent Developments

Table 55. Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 56. Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 57. Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Agilent Technologies Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) SWOT Analysis

Table 59. Agilent Technologies Business Overview

Table 60. Agilent Technologies Recent Developments

Table 61. F Hoffman La Roche Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 62. F Hoffman La Roche Pharmacogenomics Technology and Theranostics and

Companion Diagnostics (CDx) Product Overview

Table 63. F Hoffman La Roche Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. F Hoffman La Roche Business Overview

Table 65. F Hoffman La Roche Recent Developments

Table 66. Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 67. Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 68. Foundation Medicine Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. Foundation Medicine Business Overview

Table 70. Foundation Medicine Recent Developments

Table 71. Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 72. Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 73. Thermo Fisher Scientific Inc. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. Thermo Fisher Scientific Inc. Business Overview

Table 75. Thermo Fisher Scientific Inc. Recent Developments

Table 76. Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 77. Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 78. Leica Biosystems Nussloch GmbH Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Leica Biosystems Nussloch GmbH Business Overview

Table 80. Leica Biosystems Nussloch GmbH Recent Developments

Table 81. Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Basic Information

Table 82. Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Product Overview

Table 83. Pfizer Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross

Margin (2019-2024)

Table 84. Pfizer Business Overview

Table 85. Pfizer Recent Developments

Table 86. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Region (2025-2030) & (K Units)

Table 87. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Region (2025-2030) & (M USD)

Table 88. North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Country (2025-2030) & (K Units)

Table 89. North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country (2025-2030) & (M USD)

Table 90. Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Country (2025-2030) & (K Units)

Table 91. Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country (2025-2030) & (M USD)

Table 92. Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Region (2025-2030) & (K Units)

Table 93. Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Region (2025-2030) & (M USD)

Table 94. South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Country (2025-2030) & (K Units)

Table 95. South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country (2025-2030) & (M USD)

Table 96. Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Consumption Forecast by Country (2025-2030) & (Units)

Table 97. Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Country (2025-2030) & (M USD)

Table 98. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Type (2025-2030) & (K Units)

Table 99. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Type (2025-2030) & (M USD)

Table 100. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Price Forecast by Type (2025-2030) & (USD/Unit)

Table 101. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) Forecast by Application (2025-2030)

Table 102. Global Pharmacogenomics Technology and Theranostics and Companion

Diagnostics (CDx) Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx)

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD), 2019-2030

Figure 5. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size (M USD) (2019-2030)

Figure 6. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size by Country (M USD)

Figure 11. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Share by Manufacturers in 2023

Figure 12. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Revenue Share by Manufacturers in 2023

Figure 13. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Type

Figure 18. Sales Market Share of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Type (2019-2024)

Figure 19. Sales Market Share of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Type in 2023

Figure 20. Market Size Share of Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) by Type (2019-2024)

Figure 21. Market Size Market Share of Pharmacogenomics Technology and

Theranostics and Companion Diagnostics (CDx) by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Application

Figure 24. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Application (2019-2024)

Figure 25. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Application in 2023

Figure 26. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Application (2019-2024)

Figure 27. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share by Application in 2023

Figure 28. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Growth Rate by Application (2019-2024)

Figure 29. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Region (2019-2024)

Figure 30. North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Country in 2023

Figure 32. U.S. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Country in 2023

Figure 37. Germany Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Pharmacogenomics Technology and Theranostics and Companion

Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Region in 2023

Figure 44. China Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (K Units)

Figure 50. South America Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Country in 2023

Figure 51. Brazil Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share Forecast by Type (2025-2030)

Figure 65. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Sales Forecast by Application (2025-2030)

Figure 66. Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Pharmacogenomics Technology and Theranostics and Companion Diagnostics (CDx) Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GC0F93058FA2EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC0F93058FA2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

